Alvimopan
A selective peripherally acting μ-opioid antagonist with IC50 of 1.7 nM for the treatment of postoperative ileus; prevents gastrointestinal effects of intravenous morphine without affecting analgesia; orally active.Other Indication Approved (In Vitro) :Alvimopan inhibits the loperamide-stimulated [35S]GTPγS binding to membranes containing the cloned human μ-opioid receptor, with an IC50 of 1.7 nM. (In Vivo) :Alvimopan (0.1-1.0 mg/kg; p.o.) partially antagonizes the slowing of small intestinal transit of 113Sn-labelled microspheres in rats.Alvimopan (3 mg/kg; p.o.) has no effect on the visceromotor behavioural responses (VMR) induced by noxious colorectal distension (CRD) in conscious rats.
Product Specifications
CAS Number
156053-89-3
Product Name Alternative
ADL 8-2698 | LY 246736
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
10 mM in DMSO
Smiles
O=C (O) CNC ([C@H] (CN1C[C@H] (C) [C@] (C) (C2=CC=CC (O) =C2) CC1) CC3=CC=CC=C3) =O
Molecular Formula
C25H32N2O4
Molecular Weight
424.5326
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Glycine, N-[ (2S) -2-[[ (3R,4R) -4- (3-hydroxyphenyl) -3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
RPL17P19 sgRNA CRISPR Lentivector (Human) (Target 2)